46. 悪性関節リウマチ
[臨床試験数:4,183,薬物数:2,538(DrugBank:401),標的遺伝子数:183,標的パスウェイ数:219]
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00235872 (ClinicalTrials.gov) | August 2004 | 7/10/2005 | Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis | Open-Label Continuous Administration Study With Adalimumab (D2E7) in Subjects With Rheumatoid Arthritis | Rheumatoid Arthritis | Biological: adalimumab | Abbott | Abbott Japan Co.,Ltd;Eisai Co., Ltd. | Completed | 20 Years | N/A | All | 309 | Phase 3 | Japan |
2 | NCT00649545 (ClinicalTrials.gov) | July 2003 | 27/3/2008 | Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis | A Multi-Center Study of the Safety and Efficacy of Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients With Active Rheumatoid Arthritis | Rheumatoid Arthritis | Biological: adalimumab | Abbott | NULL | Approved for marketing | 18 Years | N/A | Both | N/A | NULL | |
3 | NCT00235833 (ClinicalTrials.gov) | June 2003 | 7/10/2005 | Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis | Long-term Continuously Repeated Dose Study of Adalimumab (D2E7) in Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | Biological: adalimumab | Abbott | Abbott Japan Co.,Ltd;Eisai Co., Ltd. | Completed | 20 Years | N/A | All | 25 | Phase 2 | Japan |
4 | NCT00234845 (ClinicalTrials.gov) | March 2003 | 13/9/2005 | Adalimumab in Combination With Methotrexate vs Methotrexate Alone in Early Rheumatoid Arthritis | A Multi-Centre Randomized, Double-Blind Study Comparing Adalimumab (D2E7) Plus Methotrexate With Placebo Plus Methotrexate on Work Disability in Subjects With Early Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: adalimumab;Drug: methotrexate | Abbott | NULL | Completed | 18 Years | N/A | Both | 148 | Phase 3 | United States |
5 | NCT00448383 (ClinicalTrials.gov) | September 2002 | 14/3/2007 | A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis | An Open-Label, Multi-Center Study to Assess the Safety and Efficacy of the Fully Human Anti-TNF-a Monoclonal Antibody Adalimumab (D2E7) When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis | Rheumatoid Arthritis | Biological: adalimumab | Abbott | NULL | Completed | 18 Years | N/A | Both | 6610 | Phase 3 | NULL |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT00049751 (ClinicalTrials.gov) | September 2002 | 13/11/2002 | Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis | A Multicenter Study of the Safety of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Adalimumab | Abbott | NULL | Completed | 18 Years | N/A | Both | 3000 | Phase 3 | United States |
7 | NCT00195650 (ClinicalTrials.gov) | July 2000 | 13/9/2005 | Long Term Open Label Continuation Study | A Multi-Center Continuation Study of the Human Anti-TNF Antibody D2E7 Administered as a Subcutaneous Injection in Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | Biological: Adalimumab | Abbott | NULL | Completed | 18 Years | N/A | All | 846 | Phase 3 | United States;Canada |
8 | NCT00233571 (ClinicalTrials.gov) | June 2000 | 13/9/2005 | A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis | A Multi-Centre Open Label Continuation Study With Subcutaneous D2E7 (Adalimumab) for Patients With Rheumatoid Arthritis Who Completed a Preceding Clinical Study With D2E7 (Adalimumab) | Rheumatoid Arthritis | Biological: Adalimumab 40 mg subcutaneous (SC) every other week (EOW) | Abbott | NULL | Completed | 18 Years | N/A | Both | 796 | Phase 3 | NULL |